WuXi XDC Cayman, Inc. (HK:2268) has released an update.
WuXi XDC Cayman Inc. has experienced substantial growth, with its revenue and net profit soaring, prompting the company to revise the annual caps for its existing continuing connected transactions. The proposed revisions, which are subject to shareholder approval, come as the company anticipates further expansion driven by the increasing demand for its XDC CRDMO services. The adjustments will be reviewed and potentially approved at an upcoming Extraordinary General Meeting (EGM), with WuXi Biologics, a major shareholder, abstaining from the vote.
For further insights into HK:2268 stock, check out TipRanks’ Stock Analysis page.
